

Together Ne Discover

Corporate Presentation

August 2023

Forward Looking Statements

This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own internal estimates and research. While argenx believes these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of argenx's internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

Certain statements contained in this presentation, other than present and historical facts and conditions independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include those argenx makes concerning the benefits and safety profile of VYVGART and VYVGART Hytrulo; the expected availability of VYVGART Hytrulo; the safety profile and efficacy signals from the ADHERE study; and the prospects of VYVGART Hytrulo as a treatment for chronic inflammatory demyelinating polyneuropathy ("CIDP"), including its ability to transform CIDP treatment for patients and the therapeutic potential and patient treatment experience of VYVGART Hytrulo for the treatment of CIDP. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission ("SEC") filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this presentation. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners.





Our mission is to transform severe autoimmunity

Redefining autoimmune diseases as IgG-mediated Raising expectations for what 'well-controlled' means for patients

Redefining What 'Well-Controlled' Means for the Patient

We want to transform treatment for patients

Minimize treatment burden

Achieve broad and sustained responses

Regain control of their lives, including professionally and socially



I was the type of woman that would run first thing in the morning before work, and then CIDP hit, and it was like hitting the wall at a hundred miles an hour.

VYVGART for Generalized Myasthenia Gravis

NOW TWO FDA-APPROVED PRODUCTS




Injection for Intravenous Use 400 mg/20 mL vial

V[°]VGART[®]Hytrulo


(efgartigimod alfa and hyaluronidase-qvfc)

Subcutaneous Injection 180 mg/mL and 2000 U/mL vial

VYVGART and **VYVGART Hytrulo** are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive



VYVGART Simplifies Treatment of gMG in the Community



Lowering the bar for VYVGART treatment initiation and expanding access to gMG patients

argen

Optimizing Core Launch Strategies

VYVGART launched in US, Japan, Germany, Italy

SUBMISSIONS OR APPROVALS IF 10+ COUNTRIES

17,000 addressable gMG patients

Consistent growth looking at month over month new patient starts

SCHOOL STATES YTD

Consistent prescriber growth to increase breadth of patients

>2,100 PRESCRIBERS UNITED STATES


Potential to drive earlier line uptake

VYVGART Hytrulo launched in US




Driving Sustained Growth Across the Business

Consistent Execution + Serial Innovation





Multi-dimensional Expansion to Reach Autoimmune Patients Globally



Reaching gMG Patients Across the Globe



VÝVGART[®]Hytrulo

Approvals Pending

Q3 2023

CANADA

Approvals Complete		Approvals Pending			
U.S.	JUNE 2023	JAPAN	BY Q1 2024		
		EUROPE	Q4 2023		
		CHINA	2024		



IgG Autoantibodies Serve as Unifying Biology Rationale for POC Indications




Pioneer FcRn Class of Medicines DSG-1 La/SSB PLA2R DSG-3 BP230 AChR MuSK TSHR

Contactin1 Ro/SSA Mi-2 THSd7A **MPO-ANCA** ANA NF155 **GPIIb/IIIa** HMGCR DSA NELL1 **PR3-ANCA GPCR BP180** LRP4 **JO-1 SRP** Immune complexes



gMG is just the beginning



indications with successful proof-of-concept or Phase 3 data

arge


ADHERE: Opportunity to Transform CIDP Patient Experience

Stage A Probability (%) of no relapse (alNCAT) 67% - 78% **Response rates** demonstrate IgG autoantibodies play significant role in underlying CIDP biology **Stage B** HR: 0.39 P = 0.000039Time (Weeks) # patients at risk Vyvgart Hytrulo 111 107 Placebo

adhe

61% lower risk of relapse based on time to first adjusted INCAT deterioration with VYVGART Hytrulo compared to placebo

Empasiprubart: Opportunity Across Multiple Autoimmune Diseases



Favorable safety and tolerability profile

anda Multifocal Motor Neuropathy Study

Our Path Forward

Enrolling second cohort

Topline ARDA results expected from both cohorts in 2024

On track to start proof-of-concept studies


Dermatomyositis

Delayed Graft Function in Kidney Transplant



ARGX-119: MuSK Agonist with Broad Potential in Neuromuscular Disease

clinical Broaden immunology pipeline



First-in-patient trial in CMS to serve as proof of biology

Translational work ongoing in amyotrophic lateral sclerosis (ALS)



Positioned for Long-term Franchise Growth

Neurology

Hematology and Rheumatology

Dermatology

Nephrology

gMG, CIDP, Myositis, TED, MMN, CMS, Musk MG, ALS

ITP, Sjogren's, POTS, Anca Vasculitis

Pemphigus, Bullous Pemphigoid, Dermatomyositis Membranous Nephropathy, Lupus Nephritis, AMR, DGF

Innovation Ecosystem





Steady Cadence of Upcoming Milestones

Planned Commercial Milestones VYVGART gMG Approval in China VYVGART gMG Approval in Canada VYVGART gMG Launches in EU VYVGART Hytrulo gMG Approval in US SC efgartigimod gMG Approval in EU SC efgartigimod gMG Approval in Japan By 1Q 2024 VYVGART ITP Submission in Japan

Planned Clinical Milestones

Efgartigimod

- ADHERE data in CIDP
- ADVANCE (SC) data in ITP
 40 2023
- GO/NO-GO Bullous Pemphigoid (BP) 10 2024
- POC data in Post-COVID POTS
 10 2024
- Initiate registrational trial in TED _____ 40 2023
- Initiate POC studies in ANCA and AMR 40 2023

Additional pipeline

- ARGX-117: ARDA MMN interim results
- ARGX-117: Initiate DGF POC study
- ARGX-119: Phase 1 study



By YE 2023

 \checkmark

Co-Creation Empowerment **Our mission** argenx continues... Innovation **Excellence** Humility 19

Breadth and Depth Within Autoimmune Pipeline

Program	Indication	Preclinical	Phase 1	Proof of Concept	Registrational	Commercial
VYVGARTT	gMG (IV)					
Efgartigimod	gMG (SC)					
	CIDP					
	Myositis					
	Thyroid Eye Disease					
	ITP (IV)					
	ITP (SC)					
	COVID-19 Mediated POTS					
	Sjogren's Syndrome					
	Anca Vasculitis					
	Pemphigus					
	Bullous Pemphigoid					
	Membranous Nephropathy					
	Lupus Nephritis					
	Antibody Mediated Rejection					
	Multifocal Motor Neuropathy					
	Dermatomyositis					
	Delayed Graft Function After Kidney Transplant					
ARGX-119	Neuromuscular Indications					

ITP ADVANCE-SC Trial






- Primary endpoint: Sustained platelet count ($\geq 50 \times 10^9$ /L) in $\geq 4/6$ visits between weeks 19 and 24
- Stringent endpoint in line with regulatory feedback, addressing platelet count variability
- Secondary and exploratory endpoints centre around the extent of disease control to illustrate real-world viability

Topline data expected 4Q 2023



Pemphigus ADDRESS Trial: Focus on Fast Onset and Steroid-sparing






Topline data expected 4Q 2023



PC-POTS ALPHA Trial





Followed by Open Label Extension study




COMPASS Score ≥ 35 at screening

Topline data expected 1Q 2024

Bullous Pemphigoid BALLAD Trial





(CDA)


Interim Analysis of First 40 Patients

- CR while on minimal OCS (≤0.1mg/kg/day) for ≥8 weeks at week 36
- Changes from baseline to week 36 in 24-hour average itch
- Quality of life

Followed by Open Label Extension study argenx

24


Myositis ALKIVIA Trial



Empasiprubart for Multifocal Motor Neuropathy Advancing Phase 2 ARDA Study to Cohort 2



A phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of two dose regimens of empasiprubart (ARGX-117) in adults with multifocal motor neuropathy





arge